Astellas Pharma Inc. (ALPMY, 4503.T) announced that the European Medicines Agency (EMA) has validated for review a Type II variation application for PADCEV (enfortumab vedotin).

Marketing 1on1, an SEO and link-building company operating since 2012, announced today that it has officially added local citations to its ...

Hagens Berman Urges Investors to Contact Firm Following Revelations of Integration Failure and 36% Stock Crash SAN FRANCISCO, Nov. 28, 2025 /PRNewswire/ -- Investor ...

TOP Ships Inc. (the "Company" or "TOP Ships") (NYSE American:TOPS), an international owner and operator of modern, fuel-efficient "ECO" tanker vessels ...

Results of the new PEA were strong, with an after-tax NPV of $440M (5% discount rate), LOM cash costs of $11.8/oz AgEq, and AISC of $15.8/oz AgEq, demonstrating the potential to transform Silver X ...

PHARMACORP RX INC. ("PharmaCorp" or the "Corporation") (TSXV: PCRX) a growing national platform for pharmacist-led community pharmacy ownership ...

MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has been hit with a securities fraud ...

Quarter Results/Real Estate CPI PROPERTY GROUP publishes financial results for the third quarter of 2025 28.11.2025 / 20:40 CET/CEST The ...

P/F Atlantic Petroleum (NASDAQ Copenhagen: ATLA DKK) today posts its 3rd quarter results for 2025. This announcement should be read in conjunction ...

ORLANDO, FL / ACCESS Newswire / November 28, 2025 / Laser Photonics Corporation (LPC) (NASDAQ:LASE), a leading global industrial developer of CleanTech Laser Systems for laser cleaning and other appli ...

VANCOUVER, BC, Nov. 28, 2025 /PRNewswire/ - New Pacific Metals Corp. ("New Pacific" or the "Company") (TSX: NUAG) (NYSE American: NEWP) today reported that all matters ...

Meren Energy Inc. ("Meren" or the "Company") reports the following share capital and voting rights update in accordance ...